Estrogen receptor β (ERβ) level but not its ERβcx variant helps to predict tamoxifen resistance in breast cancer

被引:130
作者
Esslimani-Sahla, M
Simony-Lafontaine, J
Kramar, A
Lavaill, R
Mollevi, C
Warner, M
Gustallsson, JÅ
Rochefort, H
机构
[1] INSERM, U540, F-34090 Montpellier, France
[2] Canc Ctr Val Aurelle, Dept Pathol, Montpellier, France
[3] Canc Ctr Val Aurelle, Dept Biostat, Montpellier, France
[4] Karolinska Inst, Dept Med Nutr & Biosci, Novum, Huddinge, Sweden
关键词
D O I
10.1158/1078-0432.CCR-04-0389
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The antiestrogen tamoxifen, a major endocrine therapy of estrogen receptor (ER)-positive breast cancer, is nevertheless inefficient in 30 to 40% of cases for unknown reasons. We retrospectively studied 50 ER-positive primary breast carcinomas. All of the patients had received tamoxifen as the only adjuvant therapy. They were divided into two groups depending on whether they relapsed within 5 years (16 tamoxifen-resistant cases) or did not relapse within 5 years (34 tamoxifen-sensitive cases). The expression of total ERR protein, and of ERbetacx protein, was estimated anonymously in formalin-fixed, paraffin-embedded tumor sections, by using specific antibodies and quantifiying nuclear immunostaining with a computer image analyzer. All of the tumors were found to be HER-2/neu-negative by inummohistochemistry. Univariate analysis showed that Scarff-Bloom-Richardsson grade modified by Elston (SBR grade; P < 0.001), tumor size (P = 0.042), and MIB-1 proliferation index (P = 0.02) were significantly higher in tamoxifen-resistant tumors. A low level of total ERR, whether in percentage of positive cells or in quantitative inummocytochemical (QIC) score, was also associated with tamoxifen resistance (P = 0.004). ERbetacx expression and lymph node status were similar between the two groups. The expression of ERR in the total population was positively correlated with ERbetacx (r = 0.63, P < 0.001), and was independent of the other parameters. In a multivariate analysis, ERR expression was the most important variable (P = 0.001), followed by SBR grade (I+II versus III; P = 0.008), and MIB-1 (P = 0.016). To conclude, tamoxifen resistance is associated with classical variables of aggressive tumors (high SBR grade, proliferation index, and tumor size) but not with node invasiveness. Low ERR level is an additional independent marker, better than ER(x level, to predict tamoxifen resistance.
引用
收藏
页码:5769 / 5776
页数:8
相关论文
共 36 条
[1]   Endocrine-responsive breast cancer and strategies for combating resistance [J].
Ali, S ;
Coombes, RC .
NATURE REVIEWS CANCER, 2002, 2 (02) :101-+
[2]  
[Anonymous], 1992, Lancet, V339, P1
[3]   THE ANTIPROLIFERATIVE EFFECT OF TAMOXIFEN IN BREAST-CANCER CELLS - MEDIATION BY THE ESTROGEN-RECEPTOR [J].
BARDON, S ;
VIGNON, F ;
DEROCQ, D ;
ROCHEFORT, H .
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 1984, 35 (2-3) :89-96
[4]   ROLE OF THE 2 ACTIVATING DOMAINS OF THE ESTROGEN-RECEPTOR IN THE CELL-TYPE AND PROMOTER-CONTEXT DEPENDENT AGONISTIC ACTIVITY OF THE ANTIESTROGEN 4-HYDROXYTAMOXIFEN [J].
BERRY, M ;
METZGER, D ;
CHAMBON, P .
EMBO JOURNAL, 1990, 9 (09) :2811-2818
[5]   HISTOLOGICAL GRADING AND PROGNOSIS IN BREAST CANCER - A STUDY OF 1409 CASES OF WHICH 359 HAVE BEEN FOLLOWED FOR 15 YEARS [J].
BLOOM, HJG ;
RICHARDSON, WW .
BRITISH JOURNAL OF CANCER, 1957, 11 (03) :359-&
[6]  
BORGNA JL, 1981, J BIOL CHEM, V256, P859
[7]  
COEZY E, 1982, CANCER RES, V42, P317
[8]   Breast cancer consensus meetings: Vive la difference? [J].
Davidson, NE ;
Levine, M .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (07) :1719-1720
[9]   Functional differences between the amino-terminal domains of estrogen receptors α and β [J].
Delaunay, F ;
Pettersson, K ;
Tujague, M ;
Gustafsson, JÅ .
MOLECULAR PHARMACOLOGY, 2000, 58 (03) :584-590
[10]  
ELSTON CW, 1987, DIAGNOSTIC HISTOPATH, P300